scholarly journals A Novel HNF4A Mutation Causing Three Phenotypic Forms of Glucose Dysregulation in a Family

2020 ◽  
Vol 8 ◽  
Author(s):  
Suresh Chandran ◽  
Victor Samuel Rajadurai ◽  
Wai Han Hoi ◽  
Sarah E. Flanagan ◽  
Khalid Hussain ◽  
...  
2014 ◽  
Vol 54 (7) ◽  
pp. 476-484 ◽  
Author(s):  
D. S. Pavlov ◽  
E. D. Pavlov ◽  
E. V. Ganzha ◽  
V. V. Kostin ◽  
V. Yu. Ponomareva

2021 ◽  
Vol 195 ◽  
pp. 110870
Author(s):  
Jennifer K. Mann ◽  
Liza Lutzker ◽  
Stephanie M. Holm ◽  
Helene G. Margolis ◽  
Andreas M. Neophytou ◽  
...  

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 591-P
Author(s):  
AHMED A. METWALLY ◽  
DALIA PERELMAN ◽  
HEYJUN PARK ◽  
ALESSANDRA CELLI ◽  
TRACEY MCLAUGHLIN ◽  
...  

2018 ◽  
Vol 7 (11) ◽  
pp. 461 ◽  
Author(s):  
Young-Kook Kim ◽  
Juhyun Song

Long noncoding RNAs (lncRNAs) are involved in diverse physiological and pathological processes by modulating gene expression. They have been found to be dysregulated in the brain and cerebrospinal fluid of patients with neurodegenerative diseases, and are considered promising therapeutic targets for treatment. Among the various neurodegenerative diseases, diabetic Alzheimer’s disease (AD) has been recently emerging as an important issue due to several unexpected reports suggesting that metabolic issues in the brain, such as insulin resistance and glucose dysregulation, could be important risk factors for AD. To facilitate understanding of the role of lncRNAs in this field, here we review recent studies on lncRNAs in AD and diabetes, and summarize them with different categories associated with the pathogenesis of the diseases including neurogenesis, synaptic dysfunction, amyloid beta accumulation, neuroinflammation, insulin resistance, and glucose dysregulation. It is essential to understand the role of lncRNAs in the pathogenesis of diabetic AD from various perspectives for therapeutic utilization of lncRNAs in the near future.


Hepatology ◽  
2009 ◽  
Vol 49 (6) ◽  
pp. 1896-1903 ◽  
Author(s):  
Anna M.G. Cali ◽  
Ana Mayra De Oliveira ◽  
Hyeonjin Kim ◽  
Shu Chen ◽  
Miguel Reyes-Mugica ◽  
...  

Diabetes Care ◽  
2010 ◽  
Vol 33 (10) ◽  
pp. 2225-2231 ◽  
Author(s):  
F. Bacha ◽  
S. Lee ◽  
N. Gungor ◽  
S. A. Arslanian

2020 ◽  
Vol 12 (531) ◽  
pp. eaba9021
Author(s):  
Emily J. Gallagher

SIRT2 deacetylation of NLRP3 reduces inflammation and reverses age-related glucose dysregulation.


Sign in / Sign up

Export Citation Format

Share Document